Allard Kaptein

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

John C. Byrd, Bonnie K. Harrington, Susan O’Brien et al. · New England Journal of Medicine · 2015 · 891 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Inhibition of cyclo-oxygenase 2 expression in colon cells by the chemopreventive agent curcumin involves inhibition of NF-κB activation via the NIK/IKK signalling complex

Simon Plummer, Karen Holloway, Margaret M. Manson et al. · Oncogene · 1999 · 633 citations

Medicine, Oncology, Pharmacology +13

Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile

Tjeerd Barf, Todd Covey, Raquel Izumi et al. · Journal of Pharmacology and Experimental Therapeutics · 2017 · 370 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +17

Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction

Allard Kaptein, Valérie Paillard, Michael A. Saunders · Journal of Biological Chemistry · 1996 · 244 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +14

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Sarah E. M. Herman, Arnau Montraveta, Carsten Utoft Niemann et al. · Clinical Cancer Research · 2016 · 161 citations · Full text

Medicine, Oncology, Pharmacology +12